NCT05253651 2026-03-16
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
Clinical Trials
41 trialsNCT05239741 2026-03-10
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05863195 2026-03-02
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04776655 2025-10-02
LIBImAb
Azienda USL Reggio Emilia - IRCCS
Phase 3 Recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT04793958 2025-02-11
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT02563002 2024-10-03
KEYNOTE-177
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02928224 2023-12-21
BEACON CRC
Pfizer
Phase 3 Completed
NCT00079066 2023-08-04
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT04262635 2023-08-02
C-CLASSIC
Sun Yat-sen University
Phase 3 Unknown
NCT05797467 2023-05-24
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT03391934 2023-04-05
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
Phase 3 Unknown
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00655876 2022-06-14
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT05074966 2021-10-12
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
ChineseAMS
Phase 3 Unknown
NCT00265811 2020-11-09
Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 3 Completed
NCT01107639 2020-10-20
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Phase 3 Completed
NCT04525326 2020-08-25
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Unknown
NCT04509635 2020-08-12
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
Fudan University
Phase 3 Unknown
NCT00079274 2020-05-13
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00265850 2020-05-07
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02484833 2020-03-31
Erbitux MEtastatic Colorectal Cancer Strategy Study
Catholic University of the Sacred Heart
Phase 3 Completed
NCT01228734 2020-01-28
TAILOR
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT00077233 2018-05-16
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT03362684 2017-12-05
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
IntegraGen SA
Phase 3 Completed
NCT01309126 2017-07-13
PRIMUS
HiberCell, Inc.
Phase 3 Terminated
NCT00154102 2017-01-30
CRYSTAL
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT01338558 2016-11-02
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
Hoffmann-La Roche
Phase 3 Withdrawn
NCT00075686 2015-11-17
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT01030042 2015-07-15
COMETS
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase 3 Completed
NCT00499369 2014-07-31
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00678535 2014-07-21
EXPAND
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT00433927 2014-03-14
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Ludwig-Maximilians - University of Munich
Phase 3 Unknown
NCT00482222 2013-01-23
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
University of Southampton
Phase 3 Unknown
NCT00208546 2012-02-02
Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT00145314 2011-01-14
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
The Nordic Colorectal Cancer Biomodulation Group
Phase 3 Completed
NCT00061815 2010-04-12
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
Eli Lilly and Company
Phase 3 Completed
NCT00063141 2010-04-12
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Eli Lilly and Company
Phase 3 Completed